Company Overview and News

 
Sri Lankan delegation visits Vietnam for trade opportunities

2017-09-15 lankabusinessonline
Sept 15, 2017 (LBO) – A 12-member Sri Lankan delegation has visited Vietnam this month to explore trade opportunities and establish long-term connections with electronic and electrical industries.

 
Sri Lanka’s Sierra Cables rolls to Fiji

2016-11-01 bizenglish.adaderana.lk
Sierra Cables PLC, a public listed company in Sri Lanka has reached an agreement to establish a production facility in Fiji.

 
Sierra starts joint venture in Fiji to manufacture power cables

2016-11-01 lankabusinessonline
Nov 01, 2016 (LBO) – Sri Lanka’s Sierra Cables has decided to jointly invest in a new power cable manufacturing plant in Fiji, the company said in a stock exchange filing.

 
Fitch Assigns First-Time ‘BB+(lka)’ to Sierra Cables PLC

2016-07-05 bizenglish.adaderana.lk
Fitch Ratings has assigned Sri Lanka-based cable manufacturer Sierra Cables PLC (Sierra) a National Long-Term Rating of ‘BB+(lka)’. The Outlook is Stable.

 
Fitch Assigns First­Time ‘BB+(lka)’ to Sierra Cables PLC Fitch Ratings­

2016-07-04 lankabusinessonline
Fitch Ratings has assigned Sri Lanka ­based cable manufacturer Sierra Cables PLC (Sierra) a National Long­Term Rating of ‘BB+(lka)’. The Outlook is Stable.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

20h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

21h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...